无并发症亚急性B型主动脉夹层TEVAR的IRAD登记研究结局
基于IRAD数据库1996年1月至2023年9月的无并发症B型急性主动脉夹层患者,比较亚急性期(15-90天)TEVAR与最佳药物治疗的结局。4年生存率两组相似(87% vs 84%,P=.925),但sTEVAR组3年内新发夹层率更高(13.9% vs 4.8%,P=.002),均发生于TEVAR后1年内。
要点
- 无并发症B型夹层亚急性期TEVAR与药物治疗4年生存率相似。
- sTEVAR组3年内新发夹层率显著高于BMT组,且均发生于术后1年内。
- 夹层进展、动脉瘤样变、再干预、破裂、卒中及再住院率两组相当。
核心结论
- 与最佳药物治疗相比,亚急性期TEVAR的4年生存率相似。
- sTEVAR组新发夹层率更高,均发生于TEVAR后1年内。
研究设计与样本
- 国际急性主动脉夹层登记(IRAD)数据库回顾性查询,1996年1月至2023年9月。
- 纳入无并发症B型急性主动脉夹层患者,比较亚急性期(15-90天)TEVAR(63例,4.6%)与BMT(1310例,95.4%)。
- 主要结局为4年生存率,次要结局包括延迟干预、夹层进展、新发夹层、再住院、破裂及卒中。
主要发现
- 4年生存率sTEVAR组87% vs BMT组84%,P=.925。
- 3年新发夹层率sTEVAR组13.9% vs BMT组4.8%,P=.002,均发生于TEVAR后1年内。
- 夹层进展、动脉瘤样变、再干预、破裂、卒中及再住院率两组相当。
临床怎么用
- 对于无并发症亚急性B型主动脉夹层,TEVAR与BMT生存率相似,但需警惕术后1年内新发夹层风险。
- TEVAR可能在该人群中有一定作用,但需随机试验确定获益患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic endovascular aortic repair (TEVAR) for uncomplicated type B acute aortic dissection (TBAAD) remains controversial. Compared with best medical therapy (BMT), TEVAR has demonstrated benefits for aortic remodeling; however, this intervention has procedure-related risks. METHODS: The International Registry of Acute Aortic Dissection database was queried from January 1996 to September 2023 for all uncomplicated TBAAD cases. Patients receiving TEVAR during the subacute phase (sTEVAR; 15-90 days) and BMT were included in this study. Baseline comorbidities were recorded. The primary outcome was survival at 4 years. The secondary outcomes included delayed aortic interventions, progression of aortic disease, new dissection, rehospitalization, rupture, and stroke. RESULTS: During the study period, 1373 patients with uncomplicated TBAAD were entered into the registry and had follow-up data available. In addition, 63 patients (4.6%) underwent sTEVAR, and 1310 (95.4%) received BMT. The 4-year survival rate was similar between the groups (sTEVAR 87% vs BMT 84%, P = .925). At 3 years, the sTEVAR group had higher rates of new dissection (13.9% vs 4.8%, P = .002), all within 1 year of TEVAR. Progression of dissection, aneurysmal degeneration, reintervention, rupture, stroke, and rehospitalization were comparable between the groups. CONCLUSIONS: Compared with BMT, sTEVAR led to similar survival rates. New dissection was higher in the sTEVAR group. TEVAR may have a role in uncomplicated subacute TBAAD, and further randomized trials are essential to identify which patients benefit from this intervention.
引用
- Gontarz B, Leshnower B, Arnaoutakis G, et al. Outcomes of thoracic endovascular aortic repair for uncomplicated subacute type B aortic dissection in the IRAD registry. J Vasc Surg. 2026. PMID: 42805273. doi:10.1016/j.jvs.2026.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。